EUVIMEDEUVIMED entdecken
Fallbericht

A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion

Makoto Nishijima, Kentaro Ido, Yusuke Okayama, Hiroshi Okamura, Masatomo Kuno, Yosuke Makuuchi, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Mika Nakamae, Masayuki Hino, Hirohisa Nakamae

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03839-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Makoto Nishijima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphocyte Transfusion, Remission Induction, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lymphoblastic leukemia (ALL) relapsed after allogeneic hematopoietic cell transplantation (allo-HCT) has a catastrophic prognosis. Blinatumomab, a CD3/CD19-directed bispecific T cell engager, is reportedly effective for advanced B-cell ALL (B-ALL), even after allo-HCT. However, the efficacy of blinatumomab in extramedullary relapse (EMR) is controversial. Donor lymphocyte infusion (DLI) is another immunological treatment worth considering for ALL relapsed after allo-HCT. We report the case of a 56-year-old woman with B-ALL. Allo-HCT was performed during the second complete remission (CR). Thirteen months after allo-HCT, isolated EMR (iEMR) of B-ALL developed without bone marrow lesions. A third CR was achieved with 2 cycles of blinatumomab. An additional four cycles each of blinatumomab and DLI were then administered. The patient did not develop graft-versus-host disease and has confirmed 2-year treatment-free remission without a second allo-HCT. Therefore, blinatumomab was considered an effective salvage therapy for iEMR of B-ALL after allo-HCT, because iEMR could have a lower tumor burden than that seen in systemic relapse, and low tumor burden was a prognostic factor for response to blinatumomab. Furthermore, immunological consolidation therapies could only provoke graft-versus-leukemia effects if the imbalanced effector/target ratio was restored and the tumor burden was lowered through immunosurveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLymphocyte TransfusionRemission InductionHematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansFemaleMiddle AgedRecurrenceTransplantation, HomologousTreatment Outcome

Stichwörter der Autor:innen

Allogeneic hematopoietic cell transplantationB-cell acute lymphoblastic leukemiaBlinatumomabDonor lymphocyte infusionIsolated extramedullary relapse

Substanzen

Antibodies, Bispecificblinatumomab

Autor:innen und Institutionen

  • Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
  • Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. idok@omu.ac.jp.
  • Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. idok@omu.ac.jp.
  • Department of Laboratory Medicine and Medical Informatics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Preventive Medicine and Environmental Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Zitieren

APA

Nishijima, M., Ido, K., Okayama, Y., Okamura, H., Kuno, M., Makuuchi, Y., Nishimoto, M., Nakashima, Y., Koh, H., Nakamae, M., Hino, M., & Nakamae, H. (2024). A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03839-4

Vancouver

Nishijima M, Ido K, Okayama Y, Okamura H, Kuno M, Makuuchi Y, et al. A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03839-4

BibTeX
@article{Nishijima2024,
  author = {Nishijima, Makoto and Ido, Kentaro and Okayama, Yusuke and Okamura, Hiroshi and Kuno, Masatomo and Makuuchi, Yosuke and Nishimoto, Mitsutaka and Nakashima, Yasuhiro and Koh, Hideo and Nakamae, Mika and Hino, Masayuki and Nakamae, Hirohisa},
  title = {A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03839-4}
}
Kostenlos starten →